Thu, Jul 24, 2014, 2:03 AM EDT - U.S. Markets open in 7 hrs 27 mins


% | $
Click the to save as a favorite.

Elan Corporation, plc Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • vbm62 vbm62 Oct 15, 2003 3:52 PM Flag

    asked about 40 vs. 31%

    "The Phase III trial to determine if Antegren´┐Ż (natalizumab) induces remission in moderate to severe Crohn's disease, known as ENACT-1, is now completed. Elan Corporation announced on Thursday, July 24 that the trial did not meet the primary endpoint of response, which was defined as a 70 point drop in the Crohn's Disease Activity Index (CDAI) at week 10. This result appears to be due to a larger than expected placebo response rate, A PHENOMENON seen in other Crohn's disease trials over the past few years..."

    from CCFA


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.